|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 11:12
|
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l. (Business Wire)
|
|
|
BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January.
Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use.
Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity.
Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on veno...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.25 - 20:09
|
Peanut Allergy Pipeline Market Insights Report 2025 | DBV712, PVX-108 & INP20 Lead the Way - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Peanut Allergy - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.
The "Peanut Allergy - Pipeline Insight, 2025" report delivers in-depth analysis of the Peanut Allergy therapeutic landscape, highlighting over 10 companies and upwards of 12 pipeline drugs.
This report encompasses detailed drug profiles across clinical and nonclinical stages, with assessments categorized by product type, stage, route of administration, and molecule type. Moreover, it touches on inactive pipeline products, providing a comprehensive view of the current scenario and future growth prospects in Peanut Allergy treatments.
Peanut allergy is a significant focus due to its prevalence and potential severity, often leading to severe reactions such as anaphylaxis. Although strict eradication of peanuts from the diet is advised, the pervasive presence of trace peanut residues makes total avoidance difficult, propelling the need for research toward innovative therapies. Immunothe...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
